Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. [electronic resource]
Producer: 20180209Description: 943-945 p. digitalISSN:- 1528-0020
- Aminoglycosides -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents, Immunological -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Clinical Trials, Phase III as Topic -- statistics & numerical data
- Female
- Follow-Up Studies
- Gemtuzumab
- Hepatic Veno-Occlusive Disease -- chemically induced
- Humans
- Infant
- Kaplan-Meier Estimate
- Male
- Multicenter Studies as Topic -- statistics & numerical data
- Pilot Projects
- Proportional Hazards Models
- Randomized Controlled Trials as Topic -- statistics & numerical data
- Remission Induction
- Treatment Outcome
No physical items for this record
Publication Type: Letter; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.